Cary, NC, United States of America

Mohammed A Kabir

This inventor holds 10 USPTO granted patents and 12 published patent applications, plus 3 CIPO patents and 4 EPO patents. Top assignees: Salix Pharmaceuticals, Inc., Alfa Wassermann, Inc., Msd Consumer Care, Inc.. Active years: 2015-2026.

USPTO Granted Patents = 10 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 24(Granted Patents)


Location History:

  • Lakeland, TN (US) (2015)
  • Cary, NC (US) (2015 - 2023)

Company Filing History:


Years Active: 2015-2026

Loading Chart...
Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: The Innovative Journey of Mohammed A. Kabir

Introduction

Mohammed A. Kabir stands out as a notable inventor based in Cary, North Carolina. With an impressive portfolio of eight patents, Kabir has made significant contributions to the field of pharmaceuticals, especially in the area of solid dispersion forms of rifaximin.

Latest Patents

Kabir’s most recent patents focus on solid dispersions containing rifaximin, a versatile antibiotic. These patents detail the compositions and uses of these pharmaceutical formulations, emphasizing their importance in enhancing the solubility and bioavailability of the drug.

Career Highlights

Throughout his career, Kabir has held influential positions at prominent companies. His work at Salix Pharmaceuticals, Inc. and Alfa Wassermann S.p.a. has been pivotal in advancing drug development and innovation. His expertise in the field has led to the successful application of his research in real-world pharmaceutical solutions.

Collaborations

Collaboration has been a key aspect of Kabir's career. He has worked alongside talented professionals like Pam Golden and Giuseppe Claudio Viscomi, contributing to the dynamic exchange of ideas and fostering innovation in the pharmaceutical sector.

Conclusion

Mohammed A. Kabir represents a vital force in the development of advanced pharmaceutical formulations. His commitment to innovation and collaboration continues to shape the future of drug development, benefiting both the industry and patients alike.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…